Vudalimab Biosimilar - Research Grade

Human

PD-1 + CTLA-4

>1mg/ml

Human IgG1 (N208D/E233P/L234V/L235A/G236Del/S267K/Q295E/L368D/K370S/N384D/Q418E/N421D/M428L/N434S)-Kappa

Cadonilimab Biosimilar - Research Grade (ICH5208)

https://www.imgt.org/mAb-DB/

ICH3002

Q15116;P16410

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of vudalimab, a bispecific antibody built to simultaneously engage two immune checkpoint receptors, PD-1 and CTLA-4. It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. The molecule pairs the target-binding specificities of the originator in a dual-checkpoint format, making it a convenient single reagent for interrogating cooperative or additive checkpoint signaling in the same assay. Typical research applications include use as a binding and blockade reference standard, a positive control in checkpoint-blockade screens, benchmarking of internally developed anti-PD-1 or anti-CTLA-4 candidates, and characterization of dual-target engagement in cell-based systems. It is produced in a low-endotoxin, research-grade format and is available in bulk milligram-to-gram quantities to support in-vitro assay development, reagent qualification, and preclinical characterization workflows where lot-to-lot consistency and material availability matter more than clinical-grade documentation. PD-1 (PDCD1; UniProt Q15116) and CTLA-4 (UniProt P16410) are inhibitory co-receptors that restrain T-cell responses at distinct checkpoints. PD-1 is induced on activated T cells and, on engaging its ligands PD-L1 and PD-L2, recruits the phosphatase SHP-2 to dephosphorylate TCR and CD28 signaling components, dampening effector activity in peripheral tissues and the tumor microenvironment. CTLA-4 acts earlier, chiefly during priming in lymphoid tissue: it competes with the costimulatory receptor CD28 for the shared ligands CD80 and CD86, binding them with higher avidity and physically removing them by trans-endocytosis, and it contributes to regulatory T-cell suppressive function. Because the two receptors operate through non-redundant mechanisms and at different phases of the immune response, their simultaneous blockade can produce combinatorial reinvigoration of T-cell immunity, the rationale underlying dual-checkpoint targeting.

Protein PD-1, hPD-1, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, Programmed cell death protein 1, Cytotoxic T-lymphocyte protein 4, PDCD1, PD1, CD152

Detects human PD-1 and human CTLA-4

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

20mM His/Asp, pH 5.0,Contains no stabilizers or preservatives

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Vudalimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Vudalimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Vudalimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Vudalimab that binds human PD-1 + CTLA-4.